A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 332 participants.
Also called NCT05592275
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 332 participants
- Sponsor
- Registry
-
NCT05592275
-
- Other papers using this trial's data
- Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Canada, Czechia, Hungary, Israel, Japan, Poland, Spain, Türkiye, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05592275. Randomized; double masking; primary purpose treatment. Start 2023-02-03 (actual); primary completion 2025-01-22 (actual). Results posted on 2026-02-05.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
- Condition
- Heart Failure
- Intervention (Drug)
- LY3540378
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct05592275- Content hash
d9e25ab7baa70803df44781ba486a8522b754952aa2705b090febe535c777952